Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH

Prior treatment

• A subject who has the following concomitant diseases
  • liver disease, uncontrolled hypertension, uncontrolled DM, etc.

Other illness

• A subject who has past or current history of liver diseases
• A subject who has the following medical or surgical history
  • Severe cardiac diseases, Malignant tumors, Clinically significant hypersensitivity reaction to any drugs containing components of the 11β-HSD1 inhibitor or same class
• A subject who has taken the following medications
  • Systemic glucocorticoids, NSAIDs, any medication that may induce fatty liver disease, etc.

Other

• A subject who has taken IP of another study
• A subject who does not agree with appropriate methods of contraception

• A subject aged ≥19 years to ≤75 years
• Meeting all of the following criteria:
  • Screening MRI-PDFF with ≥8% steatosis
  • Screening MRE with liver stiffness ≥2.5 kPa
  • ALT or AST ≤250 IU/L at screening
• Willing to maintain the same lifestyle (exercise, alcohol consumption, diet, etc.) during the study
• Voluntarily provide written consent to participate in the study